Hormone Therapy and the Heart: What It Is and Is Not For

No topic in women’s heart health generates more confusion, and more marketing, than hormone therapy. The single most important thing a woman can know about it is also the simplest: menopausal hormone therapy is a treatment for symptoms, not a strategy for preventing heart disease. Holding that distinction clearly is what protects a woman from being misled in either direction.

The Mechanism

To understand why hormone therapy’s cardiovascular effects are complex rather than straightforwardly protective, it helps to understand what estrogen does in the vascular system and why its decline at menopause matters to cardiovascular risk.

Endogenous estrogen has several vasculoprotective properties in premenopausal women. It promotes vasodilation through nitric oxide pathways in endothelial cells, helps maintain favorable lipid profiles by raising HDL cholesterol and lowering LDL, reduces circulating inflammatory markers, and exerts antioxidant effects on the arterial wall. It also promotes healthy endothelial function more broadly: the endothelium, the cellular lining of blood vessels, regulates vascular tone, permeability, and platelet adhesion, and estrogen supports these regulatory capacities. These effects are real and contribute meaningfully to the lower cardiovascular event rate that premenopausal women have relative to age-matched men.

When estrogen declines in the menopausal transition, these vasculoprotective effects decline with it. LDL cholesterol rises, HDL falls modestly, inflammatory markers including C-reactive protein increase, and endothelial function measurably deteriorates. Blood pressure tends to rise. Visceral adiposity accumulates even without significant changes in total body weight, because estrogen had been suppressing fat deposition in that compartment through effects on adipose tissue distribution. The cardiovascular risk acceleration that occurs in the decade following menopause reflects this composite physiological shift, not any single factor.

This background makes it biologically plausible that replacing estrogen would restore some of those protective effects and reduce cardiovascular risk. The plausibility was compelling enough that observational data seemed to confirm it: large cohort studies through the 1980s and early 1990s consistently found that women who used postmenopausal hormone therapy had better cardiovascular outcomes than those who did not. The Nurses’ Health Study, among others, reported relative risk reductions for coronary heart disease in hormone therapy users that in some analyses approached 50 percent. These findings generated widespread clinical enthusiasm, and hormone therapy was prescribed not merely for symptom relief but with an implicit or explicit cardiovascular prevention rationale.

The problem, revealed decisively by randomized controlled trial evidence, is that observational associations and trial effects diverged sharply once timing and pre-existing vascular disease were properly controlled. Exogenous estrogen, particularly oral estrogen, also has a procoagulant effect through hepatic first-pass metabolism: oral estrogens increase production of clotting factors including fibrinogen and factor VII, and decrease levels of protein S, raising venous thromboembolism risk similarly to estrogen-containing contraceptives, though the doses and formulations differ. This procoagulant effect, combined with the state of a woman’s arteries at the time therapy is initiated, is central to understanding the trial results.

Transdermal estrogen preparations, delivered through patches or gels applied to the skin, bypass hepatic first-pass metabolism and do not produce the same increase in hepatic clotting factors. Pharmacological studies confirm that transdermal estrogen does not raise venous thromboembolism risk to the same degree as oral preparations, and observational studies consistently find a lower thrombotic risk profile for transdermal compared to oral routes. This distinction is clinically meaningful and influences prescribing recommendations for women with elevated thrombotic risk.

What the Evidence Shows

The Women’s Health Initiative (WHI), a large randomized placebo-controlled trial funded by the National Institutes of Health, is the pivotal source of evidence that changed clinical understanding of hormone therapy and cardiovascular risk. The trial enrolled 16,608 postmenopausal women aged 50 to 79 and assigned them to combined conjugated equine estrogen plus medroxyprogesterone acetate or matching placebo in one arm, with a parallel arm enrolling women who had undergone hysterectomy and assigning them to estrogen alone or placebo.

The combined hormone therapy arm was stopped early in 2002, after a mean of 5.2 years of follow-up, when the data and safety monitoring board determined that the overall risk-benefit profile did not support continuation. The intervention group showed higher rates of coronary heart disease events, with a relative risk of 1.29, representing a 29 percent increase over the placebo group. Stroke risk was elevated with a relative risk of 1.41. Venous thromboembolism risk was approximately doubled. Breast cancer risk was increased with a relative risk of 1.26. Against these risks, the combined therapy did reduce colorectal cancer and hip fracture rates, but the adverse cardiovascular and breast cancer signals led to the early termination.

The estrogen-alone arm, followed for a mean of 6.8 years, told a more nuanced story. Estrogen alone did not show a significant increase in coronary heart disease events overall, and in the subgroup of women aged 50 to 59 or within ten years of menopause at enrollment, point estimates suggested a possible reduction in coronary events, though the differences were not statistically significant. Stroke risk was still elevated, and venous thromboembolism risk was increased. These data, combined with mechanistic arguments about the state of the arterial wall, gave rise to what became known as the “timing hypothesis.”

The timing hypothesis, developed and formalized by Howard Hodis and colleagues at the University of Southern California, Rogerio Lobo, Frits Rosano, and others, holds that estrogen-containing therapy may have different cardiovascular effects depending on when it is initiated relative to menopause and the condition of a woman’s coronary arteries at initiation. In women who begin therapy within approximately ten years of menopause, when the arterial endothelium is relatively intact, estrogen may maintain or support vascular function through its nitric oxide and anti-inflammatory effects. In women who are more than ten years past menopause or who already have subclinical or established atherosclerosis, estrogen initiated at that point may act on a compromised and inflammatory vascular substrate in a way that destabilizes existing plaque or promotes thrombotic events, rather than offering protection.

The ELITE (Early versus Late Intervention Trial with Estradiol) trial, published in the New England Journal of Medicine in 2016, provided direct prospective evidence relevant to this hypothesis. It randomized 643 postmenopausal women to estradiol or placebo, stratified by time since menopause, and followed them with serial carotid intima-media thickness measurements. Women who were fewer than six years from menopause and who received estradiol showed significantly slower progression of carotid intima-media thickness compared to placebo, a finding interpreted as evidence of vascular benefit in early menopause. Women who were more than ten years from menopause showed no such difference. The ELITE findings do not establish hormone therapy as a cardiovascular prevention intervention, because they were not powered to demonstrate reductions in clinical events, but they support the biological plausibility of the timing hypothesis.

The Kronos Early Estrogen Prevention Study (KEEPS), which randomized 727 recently menopausal women to oral conjugated equine estrogen, transdermal estradiol, or placebo over four years, found no significant differences in carotid intima-media thickness progression across groups, and no significant differences in coronary artery calcium accumulation, though trends in the transdermal group were somewhat more favorable. KEEPS did not find harm in recently menopausal women and provided reassurance about the safety profile in that population, while also not establishing cardiovascular benefit.

The current position of major professional societies, including the American Heart Association, the American College of Cardiology, and the North American Menopause Society, is explicit: hormone therapy should not be used for cardiovascular disease prevention. The benefit-risk profile does not support that indication, and cardiovascular risk in women at and after menopause is addressed through proven risk-reduction strategies, which are the same as in any other high-risk adult population.

The Progestogen Component: Why Formulation Type Matters Beyond the Estrogen Question

The WHI trial used medroxyprogesterone acetate (MPA) as the progestogen component in its combined therapy arm. MPA is a synthetic progestin with pharmacological properties that differ meaningfully from endogenous progesterone. It carries partial glucocorticoid and androgenic receptor activity in addition to its progestogenic effects, counteracts some of estrogen’s favorable actions on endothelial function, reduces HDL cholesterol to a degree that natural progesterone does not, and may contribute to an inflammatory shift that micronized progesterone does not produce through the same mechanism or magnitude.

Micronized progesterone, which is biochemically identical to endogenous progesterone and is derived from plant precursors, has a substantially different receptor binding profile. It binds selectively to the progesterone receptor without the glucocorticoid and androgenic activity that characterizes MPA. Pharmacodynamic studies document that micronized progesterone does not impair endothelial function to the same degree as synthetic progestins and does not attenuate the HDL-raising effect of estrogen to the same extent.

The E3N French cohort study, which followed more than 80,000 postmenopausal women from the French Mutuelle Générale de l’Éducation Nationale, provided substantial observational evidence on this distinction. Analyses by Fournier and colleagues, published in the Journal of Clinical Oncology (2008) and Breast Cancer Research (2005), found that women using estrogen combined with micronized progesterone had a significantly lower incidence of breast cancer compared to those using estrogen combined with synthetic progestins. Accompanying analyses of venous thromboembolism risk also found more favorable profiles for micronized progesterone than for synthetic progestin formulations, though observational design limits causal inference.

Cardiovascular data specifically comparing MPA versus micronized progesterone remain less definitive than the breast cancer data, and no adequately powered randomized trial has directly compared these progestogen types for cardiovascular endpoints. Observational data consistently show more favorable cardiovascular risk profiles with micronized progesterone, but confounding by indication cannot be excluded. Current guidance from the British Menopause Society and the International Menopause Society acknowledges the mechanistic distinctions and the observational signals, while noting that equivalence has not been demonstrated in randomized trial data.

What the progestogen variable means for clinical framing: the WHI findings cannot be automatically generalized to every progestogen-containing regimen. The combined estrogen-plus-MPA arm produced adverse cardiovascular signals not replicated to the same degree in the estrogen-alone arm. Whether a modern regimen using transdermal estradiol plus micronized progesterone would produce different cardiovascular results than oral estrogen plus MPA is a scientifically legitimate open question. That uncertainty does not change the current guideline position against hormone therapy for cardiovascular prevention. It does mean that the 2002 WHI headline findings are not a complete description of the entire hormonal therapy landscape, and the distinction is part of an accurate clinical picture.

What to Do This Week

1. Treat hormone therapy as a symptom decision, made individually with your clinician based on the severity of your symptoms, your age, your time since menopause, your personal medical history including relevant contraindications, and your own values about the trade-offs involved. If your primary motivation for considering hormone therapy is cardiovascular protection, set that motivation aside and address cardiovascular risk through the tools that are actually proven to reduce it.

2. Do not avoid hormone therapy for cardiovascular reasons alone if you have significant menopausal symptoms and no specific contraindications. The cardiovascular evidence does not support blanket avoidance of appropriately indicated symptom therapy in appropriate candidates. A woman with bothersome vasomotor symptoms that are disrupting her sleep and function deserves an honest risk-benefit discussion, not a reflexive no based on cardiovascular concerns that may not apply to her situation.

3. Manage your cardiovascular risk through the established, evidence-based tools regardless of any hormone therapy decision. Blood pressure, LDL cholesterol, blood glucose, smoking status, weight, and physical activity are the variables that determine cardiovascular risk in menopausal women. These are each addressed through interventions with solid evidence. The menopause heart plan addresses these systematically in the context of the menopausal transition.

4. If you are considering systemic hormone therapy and have any personal or family history of blood clots, or any other thrombotic risk factor, ask specifically about transdermal estrogen preparations. Transdermal delivery avoids the hepatic procoagulant effect of oral estrogen and carries a substantially lower venous thromboembolism risk profile than oral preparations. The route of administration is a clinically significant variable, not a minor preference.

5. If you have a history of cardiovascular disease, established atherosclerosis, prior stroke, or estrogen-receptor-positive breast cancer, these factors need to be central to any hormone therapy discussion, not background information. They do not automatically make hormone therapy impossible, but they shift the risk-benefit calculation substantially and require explicit, careful consideration by a clinician who knows your full history.

Hormone therapy is a treatment for menopausal symptoms, decided on its own risk-benefit terms for each individual woman, and it is not a cardiovascular prevention strategy. Holding that distinction clearly is how a woman makes the most marketed decision in midlife health on evidence rather than on hope or fear. The cardiovascular risk acceleration that menopause brings is real, and it deserves real management through the tools that have demonstrated the capacity to reduce it.